GlassScriptPhysician profile
Eric G Ponder
NPI 1447761630
$66,853.30
in general payments reported to CMS, 2019-2025
59 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $7,709 · 2023: $18K · 2024: $10K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $12K · Consulting Fee: $3,690 · Travel and Lodging: $2,463 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,430.00 |
| Food and Beverage | $12,113.71 |
| Consulting Fee | $3,690.00 |
| Travel and Lodging | $2,463.36 |
| Education | $285.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47,042.72 | 2021-2025 | |
| Allergan, INC. | $2,457.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,230.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $1,472.54 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,187.03 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,100.83 | 2021-2025 | Aimovig |
| Pfizer INC. | $1,092.23 | 2022-2025 | |
| Lilly USA, LLC | $808.30 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $765.76 | 2021-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $764.80 | 2021-2025 | |
| Eisai INC. | $648.60 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $606.51 | 2021-2025 | Crexont, Rytary, Brekiya |
| Neurocrine Biosciences, INC. | $593.61 | 2021-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $577.36 | 2021-2025 | Gocovri, Gocovri |
| Biogen, INC. | $477.93 | 2021-2025 | Leqembi, Skyclarys, Tysabri |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $347.36 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $329.46 | 2021-2024 | Mavenclad |
| Acadia Pharmaceuticals INC | $297.52 | 2021-2025 | Nuplazid |
| Ucb, INC. | $259.69 | 2023-2025 | Fintepla, Nayzilam, Rystiggo |
| Neurelis, INC. | $222.16 | 2022-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $209.16 | 2023-2025 | Rexulti |
| Impel Pharmaceuticals INC. | $204.28 | 2022-2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $196.97 | 2021-2025 | Ultomiris |
| Octapharma USA, INC. | $191.93 | 2022-2024 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $148.57 | 2021 | |
| Horizon Therapeutics Plc | $148.04 | 2023 | Uplizna |
| Upsher-Smith Laboratories LLC | $147.20 | 2021-2023 | |
| Axsome Therapeutics, INC. | $143.73 | 2022-2025 | Sunosi, Symbravo |
| Harmony Biosciences LLC | $131.54 | 2022-2024 | Wakix |
| Avion Pharmaceuticals | $126.39 | 2022 | |
| Insightec,INC | $114.43 | 2023 | Exablate |
| Supernus Pharmaceuticals, INC. | $108.52 | 2021-2025 | Qelbree |
| Corium, LLC | $107.87 | 2022-2023 | Adlarity |
| Sk Life Science, INC. | $107.65 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $107.38 | 2022 | |
| Ani Pharmaceuticals, INC. | $107.02 | 2023 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $106.87 | 2023-2025 | Xeomin, Inbrija |
| Alnylam Pharmaceuticals INC. | $105.34 | 2021-2024 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $95.62 | 2022-2025 | Wainua |
| Sunovion Pharmaceuticals INC. | $91.50 | 2021-2022 | |
| Csl Behring | $89.22 | 2021-2023 | Hizentra |
| Genzyme Corporation | $86.34 | 2021-2024 | |
| Kyowa Kirin, INC. | $85.99 | 2021-2023 | Nourianz |
| Ge Healthcare | $72.21 | 2023-2024 | |
| Averitas Pharma INC. | $64.68 | 2024-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $63.98 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $51.41 | 2021 | |
| Revance Therapeutics, INC. | $46.88 | 2024 | Daxxify |
| Celgene Corporation | $41.67 | 2022-2024 | Zeposia |
| Scilex Pharmaceuticals INC. | $37.87 | 2024-2025 | |
| Microtransponder, INC. | $34.03 | 2025 | |
| Arbor Pharmaceuticals, INC. | $32.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.02 | 2024 | Hyqvia |
| Greenwich Biosciences, INC. | $25.14 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.63 | 2023 | Horizant |
| Boston Scientific Corporation | $24.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $22.73 | 2023 | Quviviq |
| C2n Diagnostics, LLC | $21.65 | 2025 | Precivityad2 |
| Genentech USA, INC. | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ponder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.